Skip Navigation

Eligible for a Bard PowerPort lawsuit?

Plaintiff in Bard PowerPort Bellwether Lawsuit Dies Before Summer Trial

Plaintiff in Bard PowerPort Bellwether Lawsuit Dies Before Summer Trial

A plaintiff selected to serve as one of the first Bard PowerPort lawsuits to go before a jury in the federal court system has died, casting uncertainty over whether the summer trial date will proceed as planned.

The case is one of a series of Bard PowerPort bellwether trials scheduled to begin over the next year, with the first lawsuit still expected to go before a jury in April 2026, involving claims brought by a different plaintiff.

The claims were selected as representative bellwethers to gauge how juries may respond to similar evidence and testimony likely to be repeated throughout more than 3,000 Bard PowerPort lawsuits being pursued in the federal court system. Each of the lawsuits involve allegations that design defects with the implantable vascular access device (TIVAD) increase the risk of port catheter infections, fractures and migration injuries.

The Bard PowerPort, also known as a port catheter, has been marketed as a safe and effective way to give physicians a reliable means for delivering drugs directly into a patient’s bloodstream when repeated injections are expected, such as during chemotherapy. The system consists of a small injection port where the needle is inserted, which connects to a polyurethane catheter that delivers medication. 

However, plaintiffs now claim that the use of barium sulfate in the construction of the port catheter systems has caused premature breakdown of the implants, resulting in catheter fractures and migrations, as well as infections, blood clots, vascular damage and, in some cases, death.

Similar claims over the use of barium sulfate have also been presented in more than 300 Angiodynamics port catheter lawsuits.

Bard PowerPort Lawsuit Lawyers
Bard PowerPort Lawsuit Lawyers

Given common questions of fact and law, all federal Bard PowerPort lawsuits are consolidated in the District of Arizona before U.S. District Judge David G. Campbell for coordinated discovery and pretrial proceedings.

Early in the litigation, Judge Campbell ordered the parties to prepare a series of “bellwether” cases for early test trials, to help the parties evaluate the strengths and weaknesses of their arguments, evidence and expert testimony, as well as promote potential Bard PowerPort lawsuit settlements that may resolve the claims.

Last year, the court selected six Bard PowerPort bellwether lawsuits that have been undergoing preparations for a series of trial dates set to begin between April 2026 and February 2027. One of those cases was a lawsuit filed by Wanda Miller, whose case was scheduled to go to trial on July 7, 2026.

However, Miller’s death was announced in a joint memorandum (PDF) issued last week. Lawyers involved in the case met with Judge Campbell for a case management conference held on February 19, to discuss the impact of the death.

According to a memorandum submitted in advance of the meeting, Miller’s health took a “significant downturn” in late January, and she was placed in hospice due to cancer. She died on February 2.  

Plaintiffs’ leadership indicates that they were unable to perform a preservation deposition before Miller’s death because she was uncommunicative due to the advanced state of her cancer. Bard PowerPort lawsuit attorneys indicate they will consult with Miller’s family “to inquire whether an estate will be opened and a representative appointed, and whether that representative wishes to continue Mrs. Miller’s case.”

Bard PowerPort Lawsuit Bellwether Trials

The first PowerPort lawsuit scheduled to go to trial involves claims by Robert Cook, which is still expected to begin on April 21, 2026. In addition to the Miller trial scheduled for July, additional bellwether trials are scheduled to begin on August 18, October 13 and December 1, 2026, and another trial is scheduled to begin on February 2, 2027.

In addition to the federal lawsuits, an additional 211 claims are centralized as part of a multicounty litigation (MCL) in New Jersey, with another 25 lawsuits filed in Arizona state court. A claim involving a Bard PowerPort lawsuit brought in Arizona is scheduled to go to trial on August 3.

While the outcomes of these early bellwether trials in both federal and state courts will not have any binding impact on other cases pending, the average jury awards are expected to have a major impact on future Bard PowerPort settlement negotiations.

However, if the bellwether trials do not result in a global agreement to settle Bard PowerPort lawsuits, Judge Campbell may begin remanding hundreds of individual claims to various U.S. District Courts nationwide for separate trials in the future.

Written By: Irvin Jackson

Senior Legal Journalist & Contributing Editor

Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends.



0 Comments


This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

Plaintiffs are asking a federal panel to consolidate a growing number of spinal cord stimulator lawsuits against Abbott and Boston Scientific, alleging defective design changes caused lead fractures, device failures and neurological injuries nationwide.
A New York woman has filed a lawsuit alleging that her long term use of Depo Provera caused her to develop a meningioma brain tumor, which she contends resulted from the manufacturer’s negligence and failure to adequately warn about the risks.
A group of plaintiffs has petitioned the U.S. Judicial Panel on Multidistrict Litigation to centralize all Dupixent lymphoma lawsuits before a single judge for coordinated pretrial proceedings, a move that could ultimately lead to bellwether trials and a global resolution of the claims.